Events, news, and information for the people who influence the business strategies of the life science industry.

BIO-Europe® 2017: Axial CEO on microbiome use against autism

Share this article

David Donabedian, CEO of Axial Biotherapeutics, chats with Mike Ward, head of content for Informa Pharma Insights, about using the microbiome to treat autism and why this R&D area is not just a passing phase. The pair discusses Axial’s technology, as well as the next steps for the emerging biotech which will enter the clinic in 2018. Axial is focused on the link between the human gut microbiome and the central nervous system; with its first clinical-stage asset the company is targeting patients with autism.

Share this article

Upcoming event

BIO-Europe Spring

23 - 25 Mar 2020, Paris, France
Connect with the right partners at Europe’s largest springtime biotech partnering event
Go to site